Cassava Sciences, Inc.

• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases. • Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact. • MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned. • The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.

Dec 9, 2024

Back to Organizations

Cassava Sciences, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (9)

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

Approvals

News

Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development